You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Portable, affordable, quantitative microchip electrophoresis system for integrated anemia and hemoglobin variant testing

    SBC: HEMEX HEALTH INC            Topic: NHLBI

    PROJECT SUMMARY Anemia is characterized by low blood hemoglobin levels and has high prevalence affecting over one-third of the worldandapos;s population or about 2.5 billion people. Anemia has numerous causes, including nutritional deficiencies, oncologic conditions, and hematologic diseases, including hemoglobin gene variants. More than 7% of the worldandapos;s population carry hemoglobin gene va ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Reversal of Tau Pathology with MSUT2 siRNA Conjugates

    SBC: DTx Pharma, Inc.            Topic: NIA

    Project Summary Genetic and pathologic evidence in andapos;pureandapos; tauopathies such as Progressive Supranuclear Palsy (PSP), Corticobasilar Degeneration (CBD) and some cases of Fronto-temporal Dementia (FTD) directly implicate tau as causing neuronal cell death, while in Alzheimer’s Disease (AD) tau accumulation correlates with development and progression of cognitive impairment. Because of ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Application of TNFRSF25 agonists for prophylaxis and treatment of graft versus host disease

    SBC: PELICAN THERAPEUTICS, INC.            Topic: NIAID

    PROJECT SUMMARY Graft-vs-Host-Disease (GVHD) is a frequent and life-threatening complication of hematopoietic stem cell transplantation (HSCT), a procedure that often represents the best treatment option for patients suffering from hematological malignancies. Even when HLA-matched family or unrelated donors are available, an unsatisfactorily high frequency (30-40%) of transplant recipients still d ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. A platform for engineering peptide ligase for building next generation peptide therapeutics.

    SBC: SCRIBE BIOSCIENCES, INC.            Topic: 400

    PROJECT SUMMARY There is an increased interest in peptide medicines in pharmaceutical research and development (Randamp;D) because peptides are recognized as highly selective and efficacious, and at the same time relatively safe and well tolerated. Chemo-enzymatic peptide synthesis (CEPS) using peptide ligases features excellent purity and yield, thus becoming an attractive method to replace tradi ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. A Genes-to-Molecules Platform for Expanding Natural Product Diversity

    SBC: Lassogen, Inc.            Topic: NCCIH

    Project Summary Natural products (NPs) and derivatives thereof provide a rich source of chemical matter for drug discovery and development. Over the past 30 years, NP-derived drugs have accounted for more than 35% of FDA approvals. Despite their demonstrated importance, development of new NPs has slowed over the past 15 years due to the lack of efficient methods for discovery, production, and opti ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Rapid Assessment of Drug Abuse from Municipal Wastewater by Smart Surface-Enhanced Raman Scattering Technique

    SBC: E-Lambda LLC            Topic: NIDA

    Rapid Assessment of Drug Abuse from Municipal Wastewater by Smart Surface-Enhanced RamanScattering Technique PROJECT SUMMARY Rapid assessment of drug abuse from municipal wastewater is a new strategy that can overcome many limitations of traditional surveillance technologies by providing a more rapid and objective measure of drug use, which can alert communities about raising problems in their ear ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Engineering a unique antibody for patients with RA

    SBC: ABWIZ BIO INC            Topic: NIAID

    RA is one of the most common chronic autoimmune disorders that can lead to complete joint destruction and severe disability if untreated. There is no cure for RA and up to 50% of RA patients do not respond to anti-TNF therapies as circulating Th-17/IL-17 levels are highly elevated subsequent to TNF blockade. For this subset of RA patients, disruption of a novel pathway that impairs the synergy bet ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. HBI-002 to Prevent Anthracycline-Related Cardiotoxicity

    SBC: Hillhurst Biopharmaceuticals, Inc.            Topic: NHLBI

    PROJECT SUMMARY There is an urgent need for the development of approaches to prevent cardiotoxicity in cancer patients being treated with anthracyclines, an important class of drugs in the treatment of cancer (e.g. doxorubicin). Anthracycline treatment-related cardiotoxicity is a major clinical problem that severely impacts patient care and also limits dose and usage. More than a quarter of patien ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. HBI-002 to Treat Ulcerative Colitis

    SBC: Hillhurst Biopharmaceuticals, Inc.            Topic: 300

    PROJECT SUMMARY There is an urgent need for the development of new approaches to treat patients suffering from Ulcerative Colitis (UC), which is estimated to impact approximately one million adults in the United States, leading to morbidity, heightened risk of cancer, and mortality. In multiple preclinical studies, we and others have defined the therapeutic potential of low-dose exogenous carbon m ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Intraoperative Analytics and Enhanced Patient Outcomes

    SBC: M&S Biotics, Inc.            Topic: NCATS

    PROJECT SUMMARY / ABSTRACT Prolonged operative times are associated with significant patient morbidity and mortality, and multiple studies have quantified the degree to which prolonged operative time increases a patientandapos;s risk of adverse complications, like infections. Similarly, ineffective asset management in the OR leads to inefficient utilization of resources and may contribute to prolo ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government